Trulicity vs Wegovy

Trulicity (dulaglutide) and Wegovy (semaglutide 2.4 mg) are both weekly injectable GLP-1 receptor agonists, but they are approved for fundamentally different primary indications. Trulicity is FDA-approved for type 2 diabetes and for reducing major adverse cardiovascular events in adults with type 2 diabetes who have cardiovascular disease or multiple risk factors. Wegovy is FDA-approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition, and for cardiovascular risk reduction.

The clinical profiles of these medications reflect their different targets. In the REWIND trial, Trulicity (dulaglutide 1.5 mg) demonstrated HbA1c reductions of approximately 0.6% relative to placebo and modest weight loss, with significant cardiovascular benefit over a median follow-up of 5.4 years. In the STEP 1 trial, Wegovy produced mean weight loss of approximately 14.9% over 68 weeks in adults without diabetes. Semaglutide 2.4 mg is dosed at a substantially higher level than typical diabetes doses and is specifically optimized for weight reduction, making it considerably more potent for that purpose than dulaglutide.

These medications should not be viewed as interchangeable alternatives. A patient with type 2 diabetes seeking glycemic control and cardiovascular protection may be appropriately treated with Trulicity, while a patient with obesity seeking meaningful weight reduction may be a candidate for Wegovy. Some patients may have both conditions, requiring careful clinical judgment about which medication -- or combination approach -- best addresses their needs. Both carry GLP-1 class side effects and safety considerations. Healthcare providers can help patients navigate the distinction between diabetes-focused and weight-focused GLP-1 therapy based on their individual diagnosis and goals.